Psoriatic arthritis: From pathogenesis to pharmacologic management

Area of Science:

• Immunology
• Genetics
• Rheumatology

Background:

• Psoriatic arthritis (PsA) pathogenesis remains incompletely understood, involving complex interactions between genetic and environmental factors.
• Genetic studies highlight associations with Major Histocompatibility Complex I and cytokine pathways.
• Environmental factors like infections and dysbiosis may trigger disease in genetically susceptible individuals.

Purpose of the Study:

• To elucidate the intricate pathogenesis of psoriatic arthritis.
• To identify key immune pathways and cellular players involved in PsA development.
• To provide a comprehensive overview of current therapeutic strategies for PsA.

Main Methods:

• Review of genomic and proteomic studies.
• Analysis of immune cell activation pathways, including Toll-like Receptors.
• Examination of the role of CD4+ T helper 17 lymphocytes and visceral adipose tissue.
• Evaluation of current therapeutic approaches.

Main Results:

• PsA pathogenesis involves a complex interplay of genetic predisposition and environmental triggers.
• Immune system activation, particularly CD4+ T helper 17 cells, is central to disease development.
• Visceral adipose tissue may exacerbate inflammation through adipokine synthesis.
• Diverse therapeutic options exist, including conventional drugs, biologics, and small molecules.

Conclusions:

• Understanding PsA pathogenesis requires integrating genetic, environmental, and immunological factors.
• Targeting specific immune pathways, such as CD4+ T helper 17 cells, is crucial.
• Personalized treatment strategies are essential for managing PsA's varied clinical presentations.